Sana Biotechnology (SANA) Common Equity (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Common Equity data on file, last reported at $119.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 42.97% year-over-year to $119.2 million; the trailing twelve-month figure through Mar 2026 stood at $119.2 million (down 42.97% YoY), and the FY2025 full-year result was $160.9 million, down 35.78% from the prior year.
• Common Equity slipped to $119.2 million in Q1 2026, from $160.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $701.7 million in Q1 2022 to a low of $119.2 million in Q1 2026.
• A 5-year average of $347.5 million and a median of $339.6 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity decreased 4.33% in 2024 and slumped 63.92% in 2025, its largest moves.
• Tracing SANA's Common Equity over 5 years: stood at $499.3 million in 2022, then plunged by 42.42% to $287.5 million in 2023, then dropped by 12.87% to $250.5 million in 2024, then sank by 35.78% to $160.9 million in 2025, then declined by 25.88% to $119.2 million in 2026.
• Business Quant data shows SANA's Common Equity at $119.2 million in Q1 2026, $160.9 million in Q4 2025, and $195.3 million in Q3 2025.